WO2012086636A1 - 生体の虚血領域の血行状態を改善又は促進するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 - Google Patents
生体の虚血領域の血行状態を改善又は促進するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 Download PDFInfo
- Publication number
- WO2012086636A1 WO2012086636A1 PCT/JP2011/079486 JP2011079486W WO2012086636A1 WO 2012086636 A1 WO2012086636 A1 WO 2012086636A1 JP 2011079486 W JP2011079486 W JP 2011079486W WO 2012086636 A1 WO2012086636 A1 WO 2012086636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon dioxide
- dioxide mist
- mist
- pressure bath
- gas
- Prior art date
Links
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims abstract description 844
- 239000003595 mist Substances 0.000 title claims abstract description 456
- 239000001569 carbon dioxide Substances 0.000 title claims abstract description 422
- 229910002092 carbon dioxide Inorganic materials 0.000 title claims abstract description 422
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims description 29
- 230000001737 promoting effect Effects 0.000 title claims description 12
- 210000004369 blood Anatomy 0.000 title abstract description 10
- 239000008280 blood Substances 0.000 title abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 80
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 21
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 7
- 238000005507 spraying Methods 0.000 claims abstract description 7
- 230000017531 blood circulation Effects 0.000 claims description 36
- 238000007599 discharging Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 abstract description 7
- 239000007789 gas Substances 0.000 description 172
- 238000011282 treatment Methods 0.000 description 60
- 238000005259 measurement Methods 0.000 description 47
- 238000010586 diagram Methods 0.000 description 34
- 241000700159 Rattus Species 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 31
- 210000002381 plasma Anatomy 0.000 description 28
- 208000028867 ischemia Diseases 0.000 description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 23
- 239000001301 oxygen Substances 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 210000003205 muscle Anatomy 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000011088 calibration curve Methods 0.000 description 10
- 210000003141 lower extremity Anatomy 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 201000002818 limb ischemia Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- -1 nitrate ions Chemical class 0.000 description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 229940126864 fibroblast growth factor Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012086 standard solution Substances 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 108010064719 Oxyhemoglobins Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000031700 light absorption Effects 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 229920002379 silicone rubber Polymers 0.000 description 3
- 230000037384 skin absorption Effects 0.000 description 3
- 231100000274 skin absorption Toxicity 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108010002255 deoxyhemoglobin Proteins 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000752 ionisation method Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000011941 photocatalyst Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003099 femoral nerve Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910000031 sodium sesquicarbonate Inorganic materials 0.000 description 1
- 235000018341 sodium sesquicarbonate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/02—Bathing devices for use with gas-containing liquid, or liquid in which gas is led or generated, e.g. carbon dioxide baths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/06—Artificial hot-air or cold-air baths; Steam or gas baths or douches, e.g. sauna or Finnish baths
- A61H33/066—Cabins therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/06—Artificial hot-air or cold-air baths; Steam or gas baths or douches, e.g. sauna or Finnish baths
- A61H33/10—Devices on tubs for steam baths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/04—Appliances for sand, mud, wax or foam baths; Appliances for metal baths, e.g. using metal salt solutions
- A61H2033/048—Baths using solutions, e.g. salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
- A61H2033/145—Devices for gas baths with ozone, hydrogen, or the like with CO2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
- A61H2035/004—Baths for specific parts of the body for the whole body except the head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0161—Size reducing arrangements when not in use, for stowing or transport
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0173—Means for preventing injuries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5007—Control means thereof computer controlled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5043—Displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5071—Pressure sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5082—Temperature sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5058—Sensors or detectors
- A61H2201/5089—Gas sensors, e.g. for oxygen or CO2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2203/00—Additional characteristics concerning the patient
- A61H2203/03—Additional characteristics concerning the patient especially adapted for animals
Definitions
- the present invention improves or promotes blood circulation in an ischemic region by bringing carbon dioxide gas into contact with the skin or mucous membrane of a living body directly or through clothing under a predetermined condition, thereby improving ischemic disease (for example, obstructive arteriosclerosis symptoms,
- ischemic disease for example, obstructive arteriosclerosis symptoms
- the present invention relates to a carbon dioxide mist pressure bath method and a carbon dioxide mist pressure bath apparatus for the prevention, improvement or treatment of ischemic heart disease and the like.
- carbon dioxide carbon dioxide: CO 2
- water-soluble water-soluble
- oil lipid-soluble
- carbon dioxide has traditionally improved the properties of water and oil. It is known that when touching the skin and mucous membrane of a living body, it penetrates into the skin of the living body and expands the blood vessels at the site of penetration to improve blood circulation.
- Carbon dioxide in the living tissue has a function of releasing oxygen carried by binding to hemoglobin in red blood cells. At high carbon dioxide concentrations, red blood cells release more oxygen. As described above, the supply of oxygen to cells by red blood cells is mainly controlled by carbon dioxide. In other words, without carbon dioxide, hemoglobin remains in a state where oxygen is bound, and cells cannot receive oxygen. CO 2 also plays an important role in in vivo metabolism. Thus, it is becoming clear that CO 2 is not merely a waste product generated as a result of the energy activity of cells but plays various important roles in the living body.
- the inventor of the present application considers various known physiological functions of carbon dioxide in the living body as described above, in particular, blood circulation promoting effects, vasodilatory effects, and metabolic function enhancing actions. When contact was made continuously, it was considered that there was an effect in improving or promoting blood circulation in the ischemic region. That is, carbon dioxide gas that permeates subcutaneously is taken into tissues (muscles) and blood.
- Blood containing a large amount of carbon dioxide gas is recognized as a so-called “oxygen deficient” state, and expands blood vessels to promote blood flow increase and also promotes new blood vessel formation (angiogenesis) in the ischemic region.
- oxygen deficient a so-called “oxygen deficient” state
- CO 2 a new blood vessel formation
- the present inventor makes the carbon dioxide gas into a mist (mist) in order to efficiently incorporate the carbon dioxide gas into the blood, that is, in a state where the carbon dioxide gas is confined in the bubble of the liquid thin film ( In this application, this is referred to as “carbon dioxide mist”), and by applying a predetermined pressure (over the internal pressure of the living body) to the skin and mucous membrane of the living body, the concentration of carbon dioxide gas taken into the blood is increased, and the ischemic region It was discovered that it improves.
- this prevention, improvement, or treatment includes an ischemic region after surgery or after implantation of an artificial organ.
- a carbon dioxide mist pressure bath method comprising: (a) a step of generating carbon dioxide mist by pulverizing and dissolving carbon dioxide into a liquid to form a mist; and (b) a carbon dioxide mist surrounding means for surrounding a living body in a sealed state. Spraying the carbon dioxide mist, and (c) parallel to the step (b), if necessary, so that the gas in the carbon dioxide mist surrounding means maintains a predetermined value higher than atmospheric pressure.
- a carbon dioxide mist pressure bath method comprising: a step of continuing for a minute; and a step of continuing the pressure bath of carbon dioxide mist by the steps (a) to (d) at least once a day for 4 weeks. Is to provide.
- pulverizing and dissolving is a process in which a liquid is pulverized into fine droplets and mixed with a gas (carbon dioxide gas).
- the step (d) is a step of continuing the supply of the carbon dioxide mist for at least 20 minutes so that the concentration of the carbon dioxide mist is not less than a predetermined value while measuring the concentration of the carbon dioxide mist in the carbon dioxide mist surrounding means.
- the supply amount of the carbon dioxide mist is controlled so that the atmospheric pressure in the carbon dioxide mist surrounding means becomes a predetermined value.
- the carbon dioxide mist contains carbon dioxide mist having a particle size of 10 ⁇ m or less. Further, the atmospheric pressure in the carbon dioxide mist surrounding means in the step (c) is 1.01 to 2.5 atm. And the density
- the present invention further improves or promotes blood circulation in an ischemic region by bringing carbon dioxide gas into contact with the skin and mucous membrane of a living body directly or through clothing, thereby preventing, improving or treating the ischemic disease of the living body.
- a carbon dioxide mist pressure bath device for generating a carbon dioxide mist surrounding the living body in a hermetically sealed state, and carbon dioxide mist obtained by pulverizing and dissolving carbon dioxide into a liquid to form a mist.
- Carbon dioxide mist generating and supplying means for supplying into the carbon dioxide mist surrounding means, discharge means for discharging the gas in the carbon dioxide mist surrounding means to the outside, and necessary for discharging the gas in the carbon dioxide mist surrounding means to the outside Accordingly, the carbon dioxide gas from the carbon dioxide mist generating and supplying means is adjusted so that the atmospheric pressure in the carbon dioxide mist surrounding means is within a predetermined value range.
- a control means for controlling the supply amount of the mist, the carbon dioxide mist pressure bath device characterized by comprising the means of the.
- the carbon dioxide mist surrounding means further comprises a concentration detection means for measuring the concentration of the carbon dioxide mist, and the control means controls the supply amount of the carbon dioxide mist so that the concentration of the carbon dioxide mist becomes a predetermined value or more. It is characterized by doing.
- the apparatus further comprises an atmospheric pressure detecting means for measuring the atmospheric pressure in the carbon dioxide mist surrounding means, and the control means controls the supply amount of the carbon dioxide mist so that the atmospheric pressure in the carbon dioxide mist surrounding means becomes a predetermined value. It is characterized by.
- the carbon dioxide mist surrounding means is a foldable cover type, bag type or fixed stationary box type which forms a space for sealing the carbon dioxide mist inside.
- the carbon dioxide mist surrounding means includes a carbon dioxide mist supply port having a check valve for introducing the carbon dioxide mist therein, a discharge port for discharging internal gas, and a living body in and out. And an opening for exposing the head of the living body from the inside of the box body, wherein the opening is a leak that prevents leakage of carbon dioxide mist from a gap between the opening and the living body.
- Preventive means are provided.
- the present invention obtains test results of various animal experiments concerning improvement or promotion of blood circulation in an ischemic region, and applies carbon dioxide mist having a concentration of a predetermined value or more to the skin and mucous membrane of a living body for a certain period or more It has been confirmed that the contact improves or promotes blood circulation in the ischemic region.
- blood nitrate ions NO 3 ⁇
- NO 3 ⁇ is a relatively stable oxidative metabolite derived from NO (nitrogen monoxide), which is the main body of the endothelial cell-derived relaxation factor EDRF in blood, and NO is released from vascular endothelial cells. From these facts, it is clearly suggested that the blood flow improvement effect by the high concentration (80 to 100%) carbon dioxide mist pressure bath treatment is related to the vascular endothelial function.
- test results of various animal experiments showing improvement or promotion of the blood circulation state in the ischemic region of the living body described in the present specification are mainly for 8-week-old Wistar rats and the like. It is clear from the correlation between many other experimental examples of this type and clinical data that they apply to living organisms.
- VEGF vascular endothelial growth factor
- GAPDH glycosyde 3-phosphate dehydrating enzyme
- mouth It is a figure which shows the ratio of FGF (fibroblast growth factor) and GAPDH synthesized 4 days after the ischemia creation of mice. It is a figure which shows the ratio of eNOS (endothelial-type NO synthase) and GAPDH synthesize
- No. 13 treated with 13 CO 2 mist. 4 is a diagram illustrating a measurement result by 12 CO 2 and of 13 CO 2 EIC chromatograms in muscle of rats.
- a detectable amount of the sample by the 12 CO 2 illustrates in a bar graph.
- a detectable amount of the processing methods different 12 CO 2 illustrates in a bar graph.
- a detectable amount of the sample by the 13 CO 2 illustrates in a bar graph.
- a detectable amount of the treatment by the 13 CO 2 illustrates in a bar graph.
- the ratio of the detected amount of the 13 CO 2 for 12 CO 2 detected amount by the sample is a diagram showing in a bar graph.
- the ratio of the detected amount of the relative 13 CO 2 12 CO 2 detected amount by the processing method is a diagram showing in a bar graph.
- FIG. 1 shows a process flow of a carbon dioxide mist pressure bath method for improving or promoting blood circulation in an ischemic region of a living body according to the present invention.
- a carbon dioxide mist generating / supplying device which will be described in detail later (in FIGS. 2 and 5)
- carbon dioxide mist is obtained by pulverizing and dissolving carbon dioxide into a liquid and atomizing it.
- the pressure bath of mist there is provided at least daily by continuing 4 weeks (e), the carbon dioxide mist pressure bath method of improving or promoting the blood circulation of the ischemic area of the living body.
- the carbon dioxide mist supply is continued for at least 20 minutes so that the carbon dioxide mist concentration in the carbon dioxide mist surrounding means is measured and the carbon dioxide mist concentration becomes a predetermined value or more. You may make it like (as described in the step (d ') shown to the (B) part of FIG. 1).
- step (e) the amount of carbon dioxide mist supplied is controlled and continued for at least 20 minutes. Preferably, continuing for 30 minutes or more is to improve or promote blood circulation in the ischemic region. Is the best.
- the carbon dioxide mist contains carbon dioxide mist having a particle size of 10 ⁇ m or less. As a result, carbon dioxide mist efficiently penetrates into the skin of the living body from the pores or skin and mucous membrane of the living body.
- the atmospheric pressure in the carbon dioxide mist surrounding means is 1.01 to 2.5 atm. Since the body pressure of the living body is almost the same as the atmospheric pressure (1 atm), in this carbon dioxide mist pressure bath method, the carbon dioxide mist is brought into contact with the skin and mucous membrane of the living body at a pressure higher than the atmospheric pressure, This further improves the permeability of carbon dioxide mist to the skin.
- the concentration of carbon dioxide mist in the carbon dioxide mist surrounding means is 60% or more.
- FIG. 28 shows the principle configuration of the means for generating the carbon dioxide mist.
- the water in the water tank T is put into a sealed container C in which the carbon dioxide pressure is applied from the carbon dioxide supply device G and the inside is in a carbon dioxide atmosphere.
- carbon dioxide gas and water are pulverized and dissolved to form carbon dioxide mist.
- FIG. 2 is a schematic diagram showing an outline of the first embodiment of the carbon dioxide mist pressure bath device for improving or promoting blood circulation in the ischemic region of the present invention.
- the carbon dioxide mist pressure bath apparatus 10 includes a carbon dioxide mist generating / supplying means 11 for generating and supplying carbon dioxide mist, and a pressure bath cover 12 (carbon dioxide mist surrounding means for surrounding the carbon dioxide mist together with a living body). ), A densitometer 13 (concentration detecting means) for measuring the concentration of carbon dioxide mist in the pressure bath cover 12 and the gas in the pressure bath cover 12 are discharged to the outside, and the concentration of the carbon dioxide mist exceeds a predetermined value.
- a control device 14 control means for controlling the supply amount of the carbon dioxide mist from the carbon dioxide mist generation and supply means 11 is provided.
- the carbon dioxide mist generation and supply means 11 includes a carbon dioxide supply means 111 for supplying carbon dioxide, a liquid supply means 112 for supplying liquid, a carbon dioxide gas from the carbon dioxide supply means 111 and a liquid from the liquid supply means 112. And carbon dioxide mist generating means 113 for generating and supplying mist-like gas mist (hereinafter referred to as carbon dioxide mist).
- the carbon dioxide supply means 111 is made of, for example, a gas cylinder and supplies carbon dioxide to the carbon dioxide mist generating means 113.
- the carbon dioxide supply means 111 is provided with a regulator for adjusting the gas pressure, although not shown.
- a heater for heating the gas and a thermometer for temperature control may be arranged.
- the liquid supply means 112 includes a pump or the like, and supplies liquid to the carbon dioxide mist generation means 113.
- supply means of gas mixed water such as an ozone water generator, may be used.
- these liquids may contain a drug effective for a user's disease, symptom, and the like.
- Drugs include, for example, antiallergic agents, anti-inflammatory agents, antipyretic analgesics, antifungal agents, anti-influenza virus agents, influenza vaccines, steroid agents, anticancer agents, antihypertensive agents, cosmetic agents, hair thickeners, hair growth agents And hair restorer.
- menthol has a refreshing action, vitamin E that promotes blood circulation, vitamin C derivative that is easily absorbed by skin tissue and has a high beautifying effect, retinol that normalizes the keratinization of the skin and protects the mucosa, and relieves irritation to the mucosa Anesthetic for removing odor, cyclodextrin for removing odors, photocatalyst with bactericidal or anti-inflammatory effect, or a composite of photocatalyst and apatite, hyaluronic acid with excellent water retention and moisturizing effect on skin, activating cells and immunity Coenzyme Q10 to improve, seed oil containing antioxidant substances and a large amount of nutrients, antioxidants, antibacterials, anti-inflammatorys, analgesics / anesthetics, immunity and other propolis, etc., alone or in combination, It is also possible to produce a synergistic effect with the physiological action of the gas.
- ethanol chlorhexidine gluconate, amphoteric surfactant, benzalkonium chloride, alkyldiaminoetherglycine acetate, sodium hypochlorite, peracetic acid, sodium sesquicarbonate, silica, popidone iodine, sodium bicarbonate may be added.
- high-concentration carbonated spring agent containing carbonate and organic acid as main components (sulfate, carbonate, organic acid, sodium dichloroisocyanurate as an example of active ingredients), disinfectant, detergent, etc. good.
- thermometer for temperature control in the liquid supply means 112.
- the carbon dioxide mist generating means 113 is an apparatus that generates carbon dioxide mist obtained by crushing and dissolving the gas supplied from the carbon dioxide supply means 111 and the liquid supplied from the liquid supply means 112 and supplying the carbon dioxide mist to the pressure bath cover 12. is there. At this time, the particle size of the mist to be generated is optimally 10 ⁇ m or less.
- various mist generating apparatuses such as an ultrasonic type, a spray type, a method using a fluid nozzle, and the like can be applied.
- the pressure bath cover 12 includes a cover body 121 that covers the skin and mucous membrane of a living body (here, as an example, a human body) and can form a space in which carbon dioxide mist is enclosed.
- FIG. 3 shows an outline of the pressure bath cover 12
- FIG. 4 shows a state in which the pressure bath cover 12 is applied to a human body.
- the cover main body 121 is composed of a bag-like member made of a pressure-resistant, non-breathable, and non-breathable material having a size capable of covering almost the whole body skin and mucous membrane of a living body. Is preferred.
- the material preferably include natural rubber, silicon rubber, polyethylene, polypropylene, polyvinylidene chloride, polystyrene, polyvinyl acetate, polyvinyl chloride, polyamide resin, and polytetrafluoroethylene.
- the bag-like cover body of FIG. 4 covers the whole body, only a part of the living body that needs to improve or promote blood circulation in the ischemic region may be enclosed in a sealed state by a carbon dioxide mist pressure bath.
- ischemic heart disease it may be a bag-like cover body in which only the upper body is enclosed in a sealed state, and obstructive arteriosclerosis in which the large blood vessels of the lower limbs are mainly occluded.
- a bag-like cover body that surrounds only the lower body in a sealed state may be used.
- the bag-shaped cover main body 121 is illustrated here, but it may have a box type shape or the like as described later.
- the cover body 121 is provided with an opening / closing part 122 so that a living body can enter and exit, and an opening part 123 for exposing the head of the living body to the outside of the cover 12. Further, a supply port 124 for introducing the carbon dioxide mist into the cover main body 121 and a discharge port 125 (discharge means) for discharging the carbon dioxide mist in the cover main body 121 are provided. Further, a safety valve (relief valve) may be provided that automatically opens the valve when the pressure bath cover 12 reaches a certain pressure or higher.
- the opening / closing part 122 is preferably composed of a wire fastener (zipper) subjected to pressure-resistant, non-breathable, and non-breathable processing.
- a hook-and-loop fastener or the like may be used.
- the opening 123 is provided in order to expose the head of the living body to the outside of the cover 12, and the periphery thereof is a leakage prevention means made of a stretchable material such as rubber in order to prevent leakage of carbon dioxide mist from the gap.
- the opening 123 is fitted to the user's neck.
- As the leakage prevention means a string, a belt, a hook-and-loop fastener, or the like may be used.
- the supply port 124 is provided in communication with the cover main body 121 to introduce the carbon dioxide mist into the pressure bath cover 12, and the carbon dioxide mist generating means 113 is connected thereto through the carbon dioxide mist supply pipe 119.
- a check valve is provided in the supply port 124 to prevent the backflow of the carbon dioxide mist.
- the discharge port 125 is a vent for adjusting the internal pressure and the concentration of carbon dioxide mist by discharging the gas in the pressure bath cover 12.
- the discharge port 125 opens and closes based on a command from the control device 14.
- the concentration meter 13 is installed in the pressure bath cover 12, measures the concentration of the carbon dioxide mist in the cover 12, and outputs the measured value to the control device 14.
- the control device 14 is composed of a computer having a CPU, a memory, and a display.
- the concentration of the carbon dioxide mist in the pressure bath cover 12 is set to a predetermined value or more (preferably 60% or more), and is further maintained.
- the discharge port 125 of the carbon dioxide mist generation supply unit 11 and the pressure bath cover 12 is controlled based on the measurement value of the densitometer 13.
- the temperature and pressure value in the pressure bath cover 12 may be controlled.
- the control apparatus 14 has a timer function, and enables the carbon dioxide mist pressure bath for the set time.
- FIG. 5 is a schematic view showing a carbon dioxide mist pressure bath apparatus 10A (first embodiment) using a spray-type carbon dioxide mist generating means.
- a spray type carbon dioxide mist generating means 113 ' is used as an example of the carbon dioxide mist generating means 113 .
- the carbon dioxide mist generating means 113 ′ includes a liquid storage portion 114 for storing the liquid from the liquid supply means 112, a nozzle 115A for discharging the carbon dioxide gas supplied from the carbon dioxide supply means 111 from the tip opening, and a liquid storage.
- a liquid suction pipe 115B that sucks up the liquid stored in the section 114 to the tip of the nozzle 115A, and a baffle 116 provided at a position facing the nozzle 115A and the tip opening of the liquid suction pipe 115B are formed.
- carbon dioxide gas is supplied from the carbon dioxide supply means 111 into the carbon dioxide mist generating means 113 ', and the carbon dioxide supply section 117A and the carbon dioxide introduction section for creating an air flow that introduces carbon dioxide around the nozzle 115A and discharges the carbon dioxide mist.
- 117B includes a carbon dioxide mist collecting unit 118A and a carbon dioxide mist deriving unit 118B for collecting and discharging the carbon dioxide mist.
- the carbon dioxide mist discharged from the carbon dioxide mist derivation unit 118B is supplied to the pressure bath cover 12 through the carbon dioxide mist supply pipe 119.
- a pressure gauge 151 is also installed in the pressure bath cover 12 in addition to the concentration meter 13.
- the control device 14 performs control based on these measured values.
- the atmospheric pressure in the pressure bath cover 12 is set to 1 atmosphere or more (more preferably 1.01 to 2.5 atmospheres). Further, when the pressure in the pressure bath cover 12 exceeds a predetermined value, control is performed such as stopping the carbon dioxide mist generation and supply means 11 and discharging the carbon dioxide mist in the pressure bath cover 12 from the discharge port 125. May be.
- a flow valve 141 is provided between the carbon dioxide supply section 117A of the carbon dioxide mist generation means 113 'from the carbon dioxide supply means 111 to provide a gas flow rate to the carbon dioxide mist generation means 113'.
- the carbon dioxide mist supply pipe 119 is provided with a switching valve 142 for switching between the carbon dioxide mist from the carbon dioxide mist derivation section 118B of the carbon dioxide mist generating means 113 'and the carbon dioxide gas from the carbon dioxide supply means 111 in the carbon dioxide mist supply means 113'
- the carbon dioxide mist concentration in the cover 12 can be adjusted.
- the user opens the opening / closing part 122 of the pressure bath cover 12 and enters the cover main body 121, closes the opening / closing part 122 after properly aligning the opening 123 with the neck, and the inside of the pressure bath cover 12 is sealed. To be.
- the liquid from the liquid supply means 112 is injected into the liquid reservoir 114 of the carbon dioxide mist generating means 113 ′, and then the carbon dioxide gas is supplied from the carbon dioxide supply means 111 to the carbon dioxide mist generating means 113 ′.
- the generated carbon dioxide mist passes through the carbon dioxide mist collecting unit 118A and the carbon dioxide mist derivation unit 118B, and is supplied from the carbon dioxide mist supply pipe 119 to the pressure bath cover 12.
- the control device 14 controls the carbon dioxide mist generation supply means 11 and the discharge port 125 of the pressure bath cover 12 based on the values of the concentration meter 13 and the pressure gauge 151.
- the carbon dioxide mist pressure bath is performed until a predetermined time of a preset timer elapses.
- the gas mist supply pipe 119 is preferably composed entirely or partially of a flexible bellows-like pipe having a large pipe diameter. Since the bellows-like tube can be freely bent and expanded and contracted, it does not limit the movement of the user. Furthermore, by forming a groove in the axial direction of the bellows-shaped tube inside the bellows-shaped tube, when the gas mist flowing in the gas mist supply tube 119 is liquefied, it is possible to easily collect and collect droplets. .
- the carbon dioxide mist is supplied to the pressure bath cover 12 from the single carbon dioxide mist generation / supply means 11 through the single supply port 124.
- a plurality of carbon dioxide mist generation / supply means Carbon dioxide mist may be supplied through the supply port.
- the human body is described as an example of a living body to which the carbon dioxide mist pressure bath apparatus 10 is applied.
- the living body is not limited to a human body, and may be an animal (for example, a racehorse or a pet).
- FIG. 6 is a schematic view showing a state in which a carbon dioxide mist pressure bath apparatus including a plurality of carbon dioxide mist generation and supply means is applied to a horse as an example.
- a carbon dioxide mist pressure bath apparatus including a plurality of carbon dioxide mist generation and supply means
- symbol is attached
- the carbon dioxide mist pressure bath apparatus 20 includes a plurality (here, two as an example) of carbon dioxide mist generation and supply means 21A and 21B.
- the pressure bath cover 22 for horses is formed in such a size that the cover body 221 covers almost the whole body of the horse, and includes an opening / closing part 222 and an opening part 223, and a plurality of (here, two as an example) supply ports. 224A and 224B and a discharge port 225 are provided.
- the supply ports 224A and 224B are connected to carbon dioxide mist generation and supply means 21A and 21B, respectively.
- the carbon dioxide mist may be generated from different liquids and the action of various liquids may be exerted on the living body.
- FIG. 7 is a schematic diagram showing an outline of a carbon dioxide mist pressure bath apparatus (second embodiment) including a box-type pressure bath cover that can be fixedly installed.
- the same parts as those in FIG. 2 are denoted by the same reference numerals, and detailed description thereof is omitted.
- FIG. 8 shows an outline of a box-type pressure bath cover according to this embodiment
- FIG. 9 shows a state in which this is applied to a human body.
- the carbon dioxide mist pressure bath device 30 includes a carbon dioxide mist generating / supplying means 11 for generating and supplying carbon dioxide mist, and a pressure bath cover 32 for surrounding the carbon dioxide mist together with a living body (a carbon dioxide mist enclosure). Means), a densitometer 13 (concentration detecting means) for measuring the concentration of the carbon dioxide mist in the pressure bath cover 32, and the gas in the pressure bath cover 32 are discharged to the outside, and the concentration of the carbon dioxide mist is not less than a predetermined value. And a control device 14 (control means) for controlling the amount of carbon dioxide mist supplied from the carbon dioxide mist generation / supply means 11.
- a pressure gauge 151 is provided, and the control device 14 stops the carbon dioxide mist generation / supply means 11 when the atmospheric pressure in the pressure bath cover 32 exceeds a predetermined value, and stops the carbon dioxide mist generation and supply means 11 from the discharge port 329. It is also possible to perform control such as discharging the carbon dioxide mist. Further, a safety valve (relief valve) may be provided that automatically opens the valve when the pressure bath cover 32 reaches or exceeds a certain pressure.
- the pressure bath cover 32 is composed of a box-type cover body 321 having a size capable of covering almost the entire living body. That is, it is formed of an upper portion 322, a bottom portion 323, and a plurality (here, four) of side portions 324 (324A, 324B, 324C, 324D).
- one side portion (here, 324A as an example) is a door 325 that can be opened and closed as shown in FIG. 8B because the user goes in and out of the pressure bath cover 32.
- the door 325 is provided with a handle 325A outside. Although not shown, it is preferable to provide a handle on the inside so that the door 325 can be opened and closed from the inside of the cover 32.
- the upper part 322 of the cover body 321 is provided with an opening 326 for exposing the user's head to the outside of the cover 32.
- the opening 326 has a diameter that allows the head to be taken in and out with a margin.
- a leakage prevention means 327 is provided around the opening 326 in order to prevent leakage of carbon dioxide mist from the gap.
- a non-breathable material for example, a polyethylene sheet
- an elastic member such as rubber is attached to the edge of the opening 327A to fit the user's neck.
- a string, a belt, a hook-and-loop fastener or the like may be used instead of rubber.
- the pressure bath cover 32 is connected to a carbon dioxide mist supply pipe 119 and includes a supply port 328 for introducing the carbon dioxide mist into the inside.
- a check valve is provided inside the supply port 328 to prevent the backflow of the carbon dioxide mist.
- the pressure bath cover 32 includes a discharge port 329 for adjusting the internal pressure and the concentration of carbon dioxide mist by discharging the gas in the pressure bath cover 12. The discharge port 329 opens and closes based on a command from the control device 14.
- a chair 330 is arranged in the pressure bath cover 32 so that the user can perform the carbon dioxide mist pressure bath in the sitting position. It is preferable to use the chair 330 that can change the height of the seating surface according to the seating height of the user.
- the user When performing the carbon dioxide mist pressure bath using the pressure bath cover 32 of the present embodiment, the user first opens the door 325 of the cover 32 and enters the cover main body 321, and the position of the head is relative to the opening 326. Adjust the height of the chair 330 to be appropriate. Next, the user sits on the chair 330, passes the head through the opening 326, and further sets the leakage prevention means 327 around the neck to prevent leakage of carbon dioxide mist. Then, the door 325 is closed to close the cover 32. In this state, carbon dioxide mist is supplied from the carbon dioxide mist generation supply means 11 to perform a carbon dioxide mist pressure bath.
- FIG. 10 shows an example of the shape of the pressure bath cover 32 when the carbon dioxide mist pressure bath is performed in another posture.
- FIG. 10A shows a pressure bath cover 32a for standing.
- the standing pressure bath cover 32a is formed in a vertically long shape.
- the cover body 321a is provided with an opening 326a and leakage prevention means 327a. Further, a carbon dioxide mist supply port 328a, a discharge port 329a, and a door 325a for entering and exiting are provided.
- FIG. 10B shows a pressure bath cover 32b for supine.
- the pressure bath cover 32b for the supine is formed in a horizontally long shape.
- the cover body 321b is provided with an opening 326b and leakage prevention means 327b. Further, a carbon dioxide mist supply port 328b, a discharge port 329b, and a door 325b for entering and exiting are provided.
- the living body to which the pressure bath cover 32 is applied is not limited to a human body, but may be an animal (for example, a racehorse or a pet).
- FIG. 53 is a schematic cross-sectional view showing the structure of the carbon dioxide mist generating means 130.
- the carbon dioxide mist generating means 130 stores liquid in advance in advance, and the high-speed flow of the gas supplied from the carbon dioxide supply means 111 A gas mist obtained by pulverizing and dissolving the liquid and gas is generated, and the gas is further mixed and supplied to the pressure bath cover 12 shown in FIG.
- the carbon dioxide mist generating means 130 includes a connecting portion 131 connected to the gas supplying means 111, a branching portion 132 for branching the gas flow from the connecting portion 131, and a liquid storing portion 133 for storing liquid. And a nozzle 134 that discharges one of the gas flows branched by the branching portion 132, a liquid feeding pipe 135A that sends a liquid to the tip of the nozzle 134, and a liquid blown up by the gas flow discharged by the nozzle 134 to collide with the gas mist.
- the gas supply means 111 is connected to the connecting portion 131 directly or via a gas cord or the like.
- the structure of the connecting portion 131 is such that the gas cord connected to the gas supply means 111 or the direct gas supply means 111 can be connected with one touch, and various forms can be applied according to the gas supply means 111 to be connected. .
- the gas supplied from the gas supply means 10 via the connection part 131 is branched into two at the branch part 132. One is directed to the nozzle 134 and the other is directed to the gas introduction part 138. The gas toward the nozzle 134 is discharged from the nozzle tip 134A. On the other hand, the gas traveling toward the gas introduction unit 138 is guided to the junction unit 137.
- the liquid reservoir 114 of the carbon dioxide mist generating means 113 ′ shown in FIG. 5 has a structure in which the liquid is directly supplied from the liquid supply means 112. However, the carbon dioxide mist generating means 130 of FIG. Is stored and sealed. And in use, this is opened and a gas mist pressure bath is performed. However, the liquid to be stored is the same as the liquid storage section 114 of the carbon dioxide mist generating means 113 ′, and as described above, water, ionic water, ozone water, physiological saline, purified water, and sterilized purified water are used. Furthermore, a substance effective for a user's disease, symptom, etc. may be added to these liquids.
- a nozzle 134 is disposed in the center of the bottom of the liquid reservoir 133.
- the nozzle 134 protrudes from the bottom of the liquid storage part 133 and is formed in a substantially conical cylinder shape that is squeezed toward the baffle 136.
- the base end of the nozzle 134 is connected to one branch of the branch portion 132, and gas can be discharged from the tip opening 134 ⁇ / b> A of the nozzle 134.
- the liquid absorption pipe 135 ⁇ / b> A is formed between the outer peripheral surface of the nozzle 134 and the liquid absorption pipe forming member 135 having a substantially conical cylindrical shape that is slightly larger than the nozzle 134. That is, as shown in FIG. 53, by arranging the nozzle 134 so as to cover the liquid absorption pipe forming member 135, the liquid absorption pipe is formed between the outer peripheral surface of the nozzle 134 and the inner peripheral surface of the liquid absorption pipe forming member 135. 135A is formed.
- the liquid absorption tube forming member 135 is provided with a minute claw-like protrusion at the base end (substantially below the conical cylindrical portion) of the liquid absorption tube forming member 135.
- a gap is formed between the base end of the liquid and the bottom surface of the liquid storage part 133, and the liquid stored in the liquid storage part 133 is sucked up by the liquid absorption pipe 135A through this gap. Further, the front end portion 135B of the liquid suction pipe forming member 135 is opened in the vicinity of the front end opening 134A of the nozzle 134 so that the liquid sucked by the liquid suction pipe 135A hits the gas flow discharged from the nozzle 134. It is configured.
- the liquid sucked up by the liquid suction pipe 135A is blown up against the gas flow discharged from the nozzle 134, collides with the baffle 136 disposed at a position facing the tip opening 134A of the nozzle 134, and is pulverized to generate gas mist. Is done.
- the baffle 136 is fixed to the inner wall of the merging portion 137 by the baffle support portion 136A, but may be fixed to the liquid absorption pipe forming member 135 or the like.
- the gas introduction part 138 is a gas guide path from the branch part 132 provided at the lower part of the carbon dioxide mist generating means 130 to the upper part through the side surface inside the carbon dioxide mist generating means 130, and is integrated with the carbon dioxide mist generating means 130. Is formed.
- the merging portion 137 is formed of a cylindrical member disposed so as to surround the baffle 136 on the tip opening 134 ⁇ / b> A of the nozzle 134, and communicates with the gas introduction portion 138.
- the gas branched by the branching part 132 and guided to the gas introducing part 138 merges with the gas mist generated by the joining part 137 from above and to the gas mist discharge part 139 formed around the cylindrical joining part 137. And push out the gas mist.
- the supply pressure of the gas supplied from the gas introduction part 138 to the merge part 137 can be adjusted according to the size of the diameter of the gas introduction part 138.
- the gas mist supply amount of the carbon dioxide mist generating means 130 can also be adjusted.
- the gas mist concentration (mist concentration in the gas) and the particle size of the mist can be adjusted by the diameter size of the gas introduction part 138.
- the gas mist discharge part 139 is a space formed around the cylindrical merge part 137, collects the gas mist driven from the merge part 137 by the gas from the gas introduction part 138, and discharges it together with the gas.
- the gas mist repelled by the gas mist discharge unit 139 is discharged from the gas mist discharge port 139A, which is an opening disposed in the upper part of the carbon dioxide mist generating means 130, to the pressure bath cover 12.
- a gas mist supply pipe 119 is connected between the gas mist outlet 139A and the pressure bath cover 12.
- the carbon dioxide mist generating means 130 may be configured to be removable from at least a part including the liquid storage part 133 and replaceable with another new liquid storage part 133.
- the carbon dioxide mist generating means 130 is assembled, and the replacement part including the liquid storage part 133 is assembled with other parts to complete the carbon dioxide mist generating means 130 integrated with the gas introduction part 138. .
- the liquid storage part 133 is made disposable and hygiene is maintained.
- the configuration for replenishing the liquid to the liquid suction pipe 135A is omitted.
- the carbon dioxide mist generating means 130 is preferably sterilized in advance at the manufacturing stage.
- the carbon dioxide mist generating means 130 generates gas mist as follows.
- gas is supplied from the gas supply means 10 to the nozzle 34, the nozzle 134 is constricted toward the tip, so that the gas is discharged at an increased flow rate.
- the liquid in the liquid reservoir 133 is sucked up by the suction pipe 135A by the negative pressure generated by the air flow at this time, blown up by the gas at the tip 135B of the suction pipe 135A, and collides with the baffle 136 to generate gas mist.
- the particle size of the mist generated by this collision is desirably fine, and specifically, 10 ⁇ m or less is optimal. Mist thus finely pulverized can exhibit the effect of negative ions.
- the gas is guided from the gas introduction part 138 to the junction part 137 via the branch part 132, and the discharge pressure of the generated gas mist is increased.
- the generated gas mist is mixed with the gas from the branch part 132 and discharged from the gas mist outlet 139A. That is, with reference to FIG. 5, the gas mist is supplied to the pressure bath cover 12 via the carbon dioxide mist supply pipe 119.
- FIG. 54 is a schematic diagram showing an outline of a third embodiment of the carbon dioxide mist pressure bath apparatus according to the present invention.
- the pressure bath cover 150 here covers the local part of the living body (in this figure, the human forearm is shown as an example), and forms a space in which the gas mist and gas are enclosed.
- the pressure bath cover 150 includes a first cover (inner cover) 161 disposed on the inner side and a second cover (outer cover) 155 disposed on the outer side and covering the entire first cover 161 so as to be substantially sealed. And.
- the pressure bath cover 150 is preferably made of a pressure-resistant, non-breathable, moisture-impermeable material, such as natural rubber, silicon rubber, polyethylene, polypropylene, polyvinylidene chloride, polystyrene, polyvinyl acetate, It is composed of vinyl chloride, polyamide resin, polytetrafluoroethylene and the like.
- a pressure-resistant, non-breathable, moisture-impermeable material such as natural rubber, silicon rubber, polyethylene, polypropylene, polyvinylidene chloride, polystyrene, polyvinyl acetate, It is composed of vinyl chloride, polyamide resin, polytetrafluoroethylene and the like.
- the inner cover 161 is a substantially bag-shaped cover for locally covering a portion having a high gas mist absorption rate, and also functions as a heat insulating cover. That is, after the temperature of the living body cover member 150 rises with time, a relatively cold gas mist generated at room temperature is supplied, but the inner cover 161 is made of a heat insulating material so that the temperature does not rise immediately. Is preferred. By mounting the inner cover 161, it is possible to prevent vaporization of the gas mist supplied into the gas mist pressure bath.
- the inner cover 161 is particularly effective when it is attached to a part where gas mist is to be absorbed, a part where there is a large amount of sweat glands, such as the palm or the sole of the foot.
- the inner cover 161 is provided with a supply port 152 for connecting the gas mist supply pipe 119 to introduce gas mist and gas into the inner cover 161.
- a check valve is provided in the supply port 152 to prevent backflow of gas mist and gas.
- the end of the inner cover 161 is an opening 154 here. Therefore, the gas mist and gas supplied to the inner cover 161 are also supplied to the outer cover 155 through the opening 154 at the same time.
- the outer cover 155 is larger than the inner cover 161, and can cover the skin and mucous membranes of the living body and the entire inner cover 161, and is formed in a substantially bag shape.
- the opening portion of the outer cover 155 is provided with a fastening portion 157 for enabling attachment to and removal from a living body and preventing leakage of gas mist and gas enclosed therein.
- the fastening portion 157 is preferably constituted by, for example, a stretchable surface fastener. Or you may use a string, rubber
- a material that adheres to the skin of the living body may be disposed on the inner surface of the fastening portion 157.
- the adhesive material is preferably a viscoelastic gel made of, for example, polyurethane or silicone rubber. Furthermore, it is preferable that the adhesive material is detachably provided and can be replaced every time it is used or when the viscosity becomes low.
- the outer cover 155 is provided with a connecting portion 158 that is connected to the supply port 152 of the inner cover 161 and connects the inner cover 161 and the gas mist supply pipe 119 while sealing the inside of the outer cover 155.
- the outer cover 155 is preferably provided with a gas mist outlet for extracting gas mist and gas from the cover, a valve for adjusting the pressure in the cover, and the like.
- the pressure adjustment in the cover may be performed manually, but it is desirable that the pressure is adjusted automatically by the control device 160 together with the gas mist supply control based on the measurement value of the pressure gauge 171 described later.
- a safety valve (a relief valve) that automatically opens when the inside of the outer cover 155 reaches a certain pressure value or more may be provided.
- the connecting portion 158 is provided and connected to the supply port 152 of the inner cover 161.
- any configuration can be used as long as the gas mist can be supplied to the inner cover 161 while the outer cover 155 is sealed. Such a form may be applied.
- a pressure gauge 171 for measuring the internal pressure is installed in the outer cover 155.
- the control device 160 generates and supplies gas mist based on the measured value of the pressure gauge 171 in order to keep the pressure value in the outer cover 155 at 1 atmosphere or more (more preferably, 1.01 to 2.5 atmospheres). To control. For example, the supply of gas from the gas supply means 110 is adjusted and stopped, or the gas mist and gas are discharged from the inner cover 161 and the outer cover 155. In this embodiment, since the pressure bath cover 150 in which the inner cover 161 is opened by the opening 154 is used, only one pressure gauge 171 needs to be provided in the outer cover 155. Further, a thermometer 172 for measuring temperature may be installed in the inner cover 161 or the outer cover 155 (in this case, the inner cover 161). The control device 160 turns on / off the gas mist supply from the measurement value of the thermometer 172.
- sensors for measuring oxygen concentration, carbon dioxide gas concentration, humidity, and the like are installed in the pressure bath cover 150, and the control device 60 controls the environment in the cover within a range of each preset value. You may make it do.
- the control device 160 includes a computer having a CPU, a memory, and a display.
- Various controls such as pressure adjustment and on / off switching of the gas supplied from the gas supply means 110 and on / off switching of the gas mist supply are performed so that the gas mist pressure bath can be performed in an optimum state.
- each means is set so that the inside of the pressure bath cover 150 is kept in an optimum state for performing the gas mist pressure bath from the measured values of sensors such as the pressure gauge 171 and the thermometer 172 installed in the pressure bath cover 150. Adjust.
- the pressure value in the pressure bath cover 150 becomes a predetermined value or more, it is preferable that the gas supply of the gas supply means 110 is stopped by the control device 160. Note that the above adjustment may be performed manually without using the control device 160.
- mice The individuals used in the experiment were male 8 to 10 week old wild type mice. These mice were anesthetized with pentobarbital, and the left thigh was dissected under a microscope to preserve the femoral nerve and the femoral movement. The vein is removed from the surrounding tissue and surgically removed. The arterectomy site is from the central side of the femoral artery to the shallow abdominal wall artery to the popliteal artery. Yes.
- NM non-treated
- OM mist treatment
- COS nitric oxide synthase
- L-NAME nitric oxide synthase
- the carbon dioxide mist treatment is performed every day for 10 minutes under anesthesia, but the lower body of the mouse is covered with a polyethylene bag, the entrance is closed with a rubber band, and then the bag is filled with gas mist.
- a laser Doppler blood flow meter is used to measure the blood flow of an individual, and this LDBF measurement is performed over time from the creation of the lower limb ischemia model to 28 days later, and the blood flow image obtained by the LDBF measurement is captured on a computer. Quantitative analysis is performed to calculate the blood flow ratio (I / N ratio) on the affected side with respect to the healthy side. In addition, after 28 days, the capillary density in the femoral adductor muscle, which is an ischemic region, is quantified after immunohistochemical staining using an anti-CD31 antibody.
- FIG. 11 shows blood flow measured with a laser Doppler blood flow meter immediately after surgery (ischemic creation) and on the 28th day of each group.
- FIG. 12 shows the change in blood flow immediately after the ischemia production of each group and after 4 days, 7 days, 14 days, 21 days, and 28 days, respectively, in I / N ratio. Immediately after ischemia, the I / N ratio was 0.1 or less in each group, and almost no blood flow was observed. At this time, the number of individuals is 14 individuals in the (NM) group, 15 individuals in the (AIRM) group, 18 individuals in the (CM) group, and 8 individuals in the (CM + L) group. This data also includes nine populations in which 100% oxygen mist is pressurized and sealed in a gas mist pressure bath means.
- the I / N ratio of the (NM) group improved to about 0.35 7 days after ischemia creation, about 0.52 after 14 days, 0.52 after 28 days, and about 0.6 after 28 days.
- the I / N ratio of the (AIRM) group recovered to about 0.5 7 days after ischemia production, but no difference from the NM group was observed after the 14th day.
- the population of 100% oxygen mist also shows a tendency similar to that of the (AIRM) group.
- CM Group I / N ratio improved to about 0.55 7 days after ischemic preparation, about 0.7 after 14 days, and 0.78 after 28 days. Significantly compared with NM group after 7 days The improvement was recognized.
- the (CM + L) group shows that the I / N ratio was suppressed by L-NAME administration although carbon dioxide mist treatment was performed.
- FIG. 13 shows the ischemic tissue (femoral adductor) of (NM) group, (AIRM) group, (CM) group, and (CM + L) group after 28 days from the ischemia preparation, and immunization with anti-CD31 antibody This is the result of tissue staining.
- FIG. 14 shows the result of quantitative analysis of capillary density per square mm in the (NM) group, (AIRM) group, (CM) group, and (CM + L) group based on FIG. 13 (CM). The group shows the highest value. The increase in capillary density observed in the CM group was not observed in the CM + L group.
- FIG. 15 to FIG. 20 the increase and decrease of mRNA expression (mRNA expression) in cells was relatively shown for each of the (NM) group, (AIRM) group, (CM) group, and (CM + L) group.
- FIG. 15, FIG. 16, and FIG. 17 show VEGF (vascular endothelial growth factor) and GAPDH (synthesized 4 days after ischemia production).
- the ratios of glyceraldehyde 3-phosphate dehydrase, FGF (fibroblast growth factor) and GAPDH, and eNOS (endothelial NO synthase) and GAPDH are shown.
- 18, 19 and 20 show the ratio of VEGF to GAPDH, the ratio of FGF to GAPDH, and the ratio of eNOS to GAPDH, which are synthesized after 7 days from the creation of ischemia, respectively.
- GAPDH is considered to be a protein that hardly fluctuates due to cell stimulation or the like, and the relative amount of VEGF, FGF, and eNOS is shown by obtaining a ratio with GAPDH that is measured simultaneously.
- FIG. 15 to FIG. 20 show that the (CM) group has increased VEGF and FGF, which have an important function in blood vessel regeneration, as compared with the other groups by carbon dioxide mist treatment.
- FIG. 21 shows the amount of nitrate contained in plasma 4 days after ischemia for each of the (NM) group, (AIRM) group, and (CM + L) group.
- the (CM) group has the highest content of nitric acid effective for vasodilatory action.
- FIG. 22 shows the measurement of the amount of oxygen in the tissue at the time of the rat lower limb ischemia model, based on the measurement of light absorption.
- the tissue oxygen saturation (StO2) which is the ratio, is shown.
- the femoral artery branch is ligated about 4 minutes after the start of measurement, and the main ligation is performed around 11 minutes.
- tissue oxygen saturation (StO2 oxyHb / totalHb) Is also significantly reduced.
- FIG. 23 and FIG. 24 show the amount of oxygen in the tissue 6 days after ischemia during carbon dioxide mist treatment and synthetic air treatment, respectively, based on light absorption measurement, and oxyhemoglobin (oxyHb), Deoxyhemoglobin (deoxyHb), oxyhemoglobin, total hemoglobin (totalHb), and tissue oxygen saturation (StO2).
- oxyHb oxyhemoglobin
- deoxyhemoglobin deoxyhemoglobin
- totalHb total hemoglobin
- StO2 tissue oxygen saturation
- FIG. 25 and FIG. 26 show the measurement of the amount of oxygen in the tissue 6 days after ischemia during the synthetic air treatment and the carbon dioxide mist treatment, respectively, oxyhemoglobin (oxyHb), deoxyhemoglobin (deoxyHb), and oxy It is shown by hemoglobin and total hemoglobin (totalHb). 25 and 26 show that the oxyhemoglobin is increased in the carbon dioxide mist treatment compared with the synthetic air treatment.
- FIG. 27 shows the “number of proteins identified by iTRAQ and LC / MS / MS” and the effect on protein by carbon dioxide mist treatment after lower limb ischemia.
- iTRAQ isobaric tags for relative and absolute quantitation
- reagents 114, 115, 116, 117
- the modified sample is mixed to obtain a sample for mass spectrometry.
- MS / MS spectrum of each peptide a signal reflecting the amino acid sequence and a reporter ion reflecting the amount of protein contained in each sample are observed. Comparing and examining the signal intensities identified in the MS / MS analysis means that comparative quantification using the quantitative ratio of each peptide is used. By this method, the effectiveness and mechanism of carbon dioxide mist on the protein expression level in cells (particularly skeletal muscle) can be clarified.
- the 13 CO 2 amount obtained from the 12 CO 2 amount is subtracted from the detected amount of 13 CO 2 , The amount of 13 CO 2 derived from skin absorption, ie absorbed by gas mist treatment, was calculated.
- Linearity Figure 29 of the calibration curve is a measured EIC chromatogram, the upper part 12 CO 2 amount, and the lower part 13 It is a chromatogram of CO 2 amount. In the chromatogram, the horizontal axis indicates the retention time, the vertical axis indicates the concentration, and the area (peak area) of the triangular portion of the normal distribution is the amount of CO 2 measured.
- Figure 30 shows a calibration curve of the created 12 CO 2, a calibration curve of a quadratic curve correlation coefficient (R) is approximated to a straight line and 0.9987.
- the RSD showed a high reproducibility of less than 20% in all the samples.
- FIGS. 31 to 46 show the measurement results by EIC chromatogram in each of the 16 samples. In each figure, the upper row shows a 12 CO 2 chromatogram, and the lower row shows a 13 CO 2 chromatogram.
- the horizontal axis retention time and the vertical axis represents the amount of CO 2 peak area was measured for each chromatogram showing the concentration, measured m / Z44 (top) and m / Z45 of CO 2 (bottom) Values are quantified by a CO 2 calibration curve with m / z 44.
- Table 1 shows the quantitative results of 12 CO 2 and 13 CO 2 in each sample.
- the chromatogram of FIG. The amount of 12 CO 2 in the plasma of 1 is shown in the upper part, and the amount of 13 CO 2 is shown in the lower part.
- the quantified result is divided by the amount of plasma, and the amount of 12 CO 2 per mass of plasma obtained is Table 1 shows that 860 ⁇ g / g and the amount of 13 CO 2 is 7.6 ⁇ g / g.
- the chromatogram of FIG. 33, 13 CO 2 mist treated No. The amount of 12 CO 2 in the plasma of 1 is shown in the upper part, the amount of 13 CO 2 is shown in the lower part, and the quantified result is divided by the amount of plasma, and the amount of 12 CO 2 per mass of plasma obtained Table 22 shows that is 960 ( ⁇ g / g) and 13 CO 2 is 59 ( ⁇ g / g).
- Table 1 the measurement results of 12 CO 2 and 13 CO 2 by chromatograms in untreated and 13 CO 2 mist-treated rat plasma, heart, liver and muscle tissues are shown as m / z44.
- the amount of 12 CO 2 and the amount of 13 CO 2 per mass of plasma are shown by quantifying with a CO 2 calibration curve, and dividing the quantified result by the amount of plasma.
- Table 1 the quantitative results are depicted in Table 1, has a value calculated by using a CO 2 calibration curves m / Z44, 13 with respect to the CO 2, the natural isotopic present in CO 2 from respiration (m / Z45). Therefore, Table 2, the detection value of the natural isotopic 12 CO 2 (m / z45) was corrected by subtracting the 13 CO 2 which is present from 13 CO 2 based on the results shown in Table 1 in CO 2 from breathing Show.
- Each 12 CO 2 detected amount of 2 is shown as a bar graph for each sample of plasma, heart, liver and muscle. In this graph, when the detected amount of 12 CO 2 in the untreated and 13 CO 2 mist treatments is compared, the detected amount of 12 CO 2 in each tissue shows a high tendency in the samples of the 13 CO 2 mist treated. It is not allowed.
- Each 12 CO 2 detected amount in 2 is shown as a bar graph for each sample of plasma, heart, liver and muscle. This graph also shows that there is no significant difference in the detected amount of 12 CO 2 due to processing.
- FIG. 1 no processing No. 2, 13 CO 2 mist treatment no. 1 and 13 CO 2 mist treatment no. 2, each 13 CO 2 detection amount (correction value) is shown as a bar graph for each sample of plasma, heart, liver and muscle. This graph shows that the amount of 13 CO 2 in each tissue is hardly detected when not treated.
- 13 CO 2 mist treatment is performed, an effective amount of 13 CO 2 is detected in each tissue of plasma, heart, liver and muscle, and carbon dioxide mist pressure bath treatment is effectively performed. ing.
- FIG. 50 shows a non-processing No. in FIG. 49 according to the non-processing and the 13 CO 2 mist processing.
- no processing No. 2 13 CO 2 mist treatment no. 1 and 13 CO 2 mist treatment no. 2 of 13 CO 2 detected amount is shown as a bar graph for each sample of plasma, heart, liver and muscle. This graph also shows that almost no amount of 13 CO 2 is detected in the case of non-treatment, but an effective amount of 13 CO 2 mist is detected in each tissue in the case of 13 CO 2 mist treatment.
- FIG. 1 no processing No. 2, 13 CO 2 treatment no. 1 and 13 CO 2 treatment no.
- the ratio of 13 CO 2 detection amount (correction value) to each 12 CO 2 detection amount of 2 is shown by a bar graph. This graph shows that in the case of non-processing, 13 CO 2 is hardly detected with respect to the detected amount of 12 CO 2 .
- 13 CO 2 mist treatment is performed, an effective amount of 13 CO 2 is detected in each tissue of plasma, heart, liver and muscle, and carbon dioxide mist pressure bath treatment is effectively performed. ing.
- FIG. 52 shows a non-processing No. in FIG. 51 according to non-processing and 13 CO 2 processing. 1, no processing No. 2, 13 CO 2 treatment no. 1 and 13 CO 2 treatment no.
- the ratio of 13 CO 2 detection amount (correction value) to each 12 CO 2 detection amount of 2 is shown by a bar graph. Also from this graph, in the case of non-treatment, 13 CO 2 is hardly detected with respect to the detected amount of 12 CO 2 , while in the case of performing 13 CO 2 mist treatment, 13 CO 2 is plasma, heart It can be seen that it is detected in the liver and muscle tissues.
- Table 3 summarizes similar experimental results for the specimens 1 to 4 of the rats in the untreated group and the specimens 1 to 4 of the rats in the 13 CO 2 treated group.
- carbon dioxide mist can be brought into contact with the skin and mucous membrane of a living body by applying a predetermined pressure (above the internal pressure of the living body), so that carbon dioxide can be efficiently taken into blood and the concentration of carbon dioxide can be increased.
- the area can be improved.
- this carbon dioxide mist pressure bath method (a) a step of generating carbon dioxide mist by pulverizing and dissolving carbon dioxide into a liquid and making it into a mist, and (b) surrounding the living body in a sealed state Spraying the carbon dioxide mist into the carbon dioxide mist surrounding means, and (c) if necessary, the step so that the gas in the carbon dioxide mist surrounding means maintains a predetermined value higher than atmospheric pressure.
- the step of discharging the gas in the carbon dioxide mist surrounding means to the outside and the step of (d) controlling the supply amount of the carbon dioxide mist to the carbon dioxide mist surrounding means for at least 20 minutes every day Continue for more than 4 weeks. This improves or promotes blood circulation in the ischemic region by bringing carbon dioxide mist into contact with the skin of the living body directly or through clothing.
- the present invention improves or promotes blood circulation in an ischemic region by bringing carbon dioxide gas into contact with the skin and mucous membrane of a living body directly or through clothing, thereby preventing, ameliorating or treating ischemic disease in the living body.
- the present invention relates to a bath method and a carbon dioxide mist pressure bath apparatus, and has industrial applicability.
- Carbon dioxide mist pressure bath apparatus 11 Carbon dioxide mist generation supply means 111 Carbon dioxide supply means 112 Liquid supply means 113 Carbon dioxide mist generation means 113 'Carbon dioxide mist generation means (mist spray type) 114 Liquid storage section 115A Nozzle 115B Liquid absorption pipe 116 Baffle 117A Carbon dioxide supply section 117B Carbon dioxide introduction section 118A Carbon dioxide mist collection section 118B Carbon dioxide mist derivation section 119 Carbon dioxide mist supply pipe 12 Pressure bath cover 121 Cover body 122 Opening / closing section 123 Opening section 124 Supply port 125 Discharge port 13 Concentration meter 14 Control device 141 Flow valve 142 Switching valve 150 Pressure bath cover 151 Pressure gauge 20 Carbon dioxide mist pressure bath devices 21A and 21B Carbon dioxide mist generation supply means 22 Horse pressure bath cover 221 Cover body 222 Opening / closing portion 223 Opening portion 224A, 224B Supply port 225 Discharge port 30 Carbon dioxide mist pressure bath device 32 Pressure bath cover 321
Abstract
Description
(1.1)測定条件の設定
(1.1.1)標準溶液の調製
炭酸ナトリウムを水に溶解して、任意の濃度の溶液を調整し、この一定量を測定用バイアルに採り、硫酸を加え密閉する。測定用バイアル内の炭酸量は、10、50、100、250、500μgの5水準とし、これら操作は、窒素ガス雰囲気のグローブボックス内で行った。
測定用バイアルの気相部を、以下の条件にてガスクロマトグラム質量分析計にて測定した。
<測定条件>
・カラム:Pora BOND Q 長さ25m・内径0.25mm・膜厚3μmm
・カラム温度:40°C(8分)
・キャリアガス:He
・試料注入法:ヘッドスペース法(60°C、1分間加熱)
・イオン化法:電子衝撃イオン化法(EI法:70eV)
・測定モード:選択イオンモニタリング(SIM)
・モニターイオン:定量イオン m/z44(12CO2)、m/z4513CO2)
標準溶液を測定し、濃度(μg/バイアル)を縦軸に、m/z44の抽出イオンカレント(EIC)クロマトグラムから検出されたCO2の量を横軸にプロットして検量線を作成した。
(1.2.1)前処理方法
試料に水酸化ナトリウム溶液を加え解凍後、乳鉢で均一にし、この一定量を測定用バイアルに採り硫酸を加え密閉した。これら操作は、窒素ガス雰囲気のグローブボックス内で行った。乳鉢で均一にした後の動作は1試料につき1乃至3回繰り返した。
前処理後の測定用バイアルの試料の測定後、m/z44のCO2検量線により、測定したm/z44及びm/z45のCO2を定量した。そして、CO2の検出量を試料量で除し、試料質量当たりの12CO2量及び13CO2量を求めた。
(2.1)測定条件の妥当性
(2.1.1)検量線の直線性
図29は、測定したEICクロマトグラムで、上段は12CO2量、下段は13CO2量のクロマトグラムである。クロマトグラムは、横軸が保持時間、縦軸が濃度を示し、正規分布の三角形状部分の面積(ピーク面積)が測定されたCO2の量となる。図30は、作成した12CO2の検量線を示すもので、相関係数(R)が0.9987と直線に近似した二次曲線の検量線である。
繰り返し測定の再現性
炭酸量が500μgの標準溶液の繰り返し測定の結果、日内再現性は相対標準偏差(RSD)が3乃至5%、試料測定間(10日間)再現性はRSDが11%であった。
図31から図46までは16通りの各試料におけるEICクロマトグラムによる測定結果を示している。各図において、上段は12CO2のクロマトグラムを示し、下段は13CO2のクロマトグラムを示している。
13CO2検出量(補正値)=13CO2検出量-12CO2検出量×0.0113/0.984
11 炭酸ガスミスト発生供給手段
111 炭酸ガス供給手段
112 液体供給手段
113 炭酸ガスミスト生成手段
113′ 炭酸ガスミスト生成手段(霧吹き式)
114 液体貯留部
115A ノズル
115B 吸液管
116 バッフル
117A 炭酸ガス供給部
117B 炭酸ガス導入部
118A 炭酸ガスミスト収集部
118B 炭酸ガスミスト導出部
119 炭酸ガスミスト供給管
12 圧浴用カバー
121 カバー本体
122 開閉部
123 開口部
124 供給口
125 排出口
13 濃度計
14 制御装置
141 流量バルブ
142 切替弁
150 圧浴用カバー
151 圧力計
20 炭酸ガスミスト圧浴装置
21A、21B 炭酸ガスミスト発生供給手段
22 馬用の圧浴用カバー
221 カバー本体
222 開閉部
223 開口部
224A、224B 供給口
225 排出口
30 炭酸ガスミスト圧浴装置
32 圧浴用カバー
321 カバー本体
322 上部
323 底部
324 側部
325 扉
325A 取手
326 開口
327 漏出防止手段
327A 開口
328 供給口
329 排出口
32a 立位用の圧浴用カバー
32b 仰臥用の圧浴用カバー
321a、321b カバー本体
325a、325b 扉
326a、326b 開口
327a、327b 漏出防止手段
328a、328b 供給口
329a、329b 排出口
330 椅子
Claims (16)
- 炭酸ガスを生体の皮膚及び粘膜に直接又は被服を通して接触させることにより虚血領域の血行を改善又は促進し、以って生体の虚血性疾患の予防、改善又は治療するための炭酸ガスミスト圧浴方法であって、
(a)炭酸ガスを液体に粉砕溶解させこれを霧状にした炭酸ガスミストを発生させるステップと、
(b)生体を密閉状態に包囲する炭酸ガスミスト包囲手段内に、前記炭酸ガスミストを噴霧するステップと、
(c)前記炭酸ガスミスト包囲手段内の気体が大気圧よりも高い所定値以上を維持するように、必要に応じて、前記ステップ(b)と並行して、前記炭酸ガスミスト包囲手段内の気体を外部に排出させるステップと、
(d)前記炭酸ガスミスト包囲手段内に対する前記炭酸ガスミストの供給を少なくとも20分間継続するステップと、
前記ステップ(a)乃至(d)による炭酸ガスミストの圧浴を、少なくとも1日一回4週間継続するステップと、
の各ステップを有することを特徴とする炭酸ガスミスト圧浴方法。 - 前記ステップ(d)は、前記炭酸ガスミスト包囲手段内における炭酸ガスミストの濃度を計測しつつ、前記炭酸ガスミストの濃度が所定値以上になるように前記炭酸ガスミストの供給を少なくとも20分間継続するステップ、であることを特徴とする請求項2に記載の炭酸ガスミスト圧浴方法。
- 前記ステップ(d)において、前記炭酸ガスミスト包囲手段内における気圧が所定値になるように前記炭酸ガスミストの供給量を制御する、ことを特徴とする請求項1又は2に記載の炭酸ガスミスト圧浴方法。
- 前記炭酸ガスミストは、その粒径が10μメートル以下の炭酸ガスミストを含有することを特徴とする請求項2に記載の炭酸ガスミスト圧浴方法。
- 前記ステップ(d)における前記炭酸ガスミスト包囲手段内における炭酸ガスミストの濃度は60%以上である、ことを特徴とする請求項4に記載の炭酸ガスミスト圧浴方法。
- 前記ステップ(c)における前記炭酸ガスミスト包囲手段内の気圧は、1.01乃至2.5気圧であることを特徴とする請求項3に記載の炭酸ガスミスト圧浴方法。
- 炭酸ガスを生体の皮膚及び粘膜に直接又は被服を通して接触させることにより虚血領域の血行を改善又は促進し、以って生体の虚血性疾患の予防、改善又は治療するための炭酸ガスミスト圧浴装置であって、
生体を密閉状態に包囲するための炭酸ガスミスト包囲手段と、
炭酸ガスを液体に粉砕溶解させこれを霧状にした炭酸ガスミストを発生させ、当該炭酸ガスミストを前記炭酸ガスミスト包囲手段内に供給する炭酸ガスミスト発生供給手段と、
前記炭酸ガスミスト包囲手段内の気体を外部に排出させるための排出手段と、
前記炭酸ガスミスト包囲手段内の気体を外部に排出させつつ、必要に応じて、前記炭酸ガスミスト包囲手段内の気圧が所定値範囲内になるように前記炭酸ガスミスト発生供給手段からの前記炭酸ガスミストの供給量を制御する制御手段と、
の各手段を備えたことを特徴とする炭酸ガスミスト圧浴装置。 - 前記炭酸ガスミスト包囲手段内における炭酸ガスミストの濃度を計測する濃度検知手段と、をさらに備え、
前記制御手段は、前記炭酸ガスミストの濃度が所定値以上になるように前記炭酸ガスミストの供給量を制御する、ことを特徴とする請求項7に記載の炭酸ガスミスト圧浴装置。 - 前記炭酸ガスミスト包囲手段内における気圧を計測する気圧検知手段と、をさらに備え、
前記制御手段は、前記炭酸ガスミスト包囲手段内における気圧が所定値になるように前記炭酸ガスミストの供給量を制御する、ことを特徴とする請求項8に記載の炭酸ガスミスト圧浴装置。 - 前記炭酸ガスミスト発生供給手段は、その粒径が10μメートル以下の炭酸ガスミストを発生させることを特徴とする請求項7に記載の炭酸ガスミスト圧浴装置。
- 前記制御手段は、前記炭酸ガスミスト包囲手段内における炭酸ガスミストの濃度を60%以上に維持することを特徴とする請求項7に記載の炭酸ガスミスト圧浴装置。
- 前記制御手段は、前記炭酸ガスミスト包囲手段内の気圧を、1.01乃至2.5気圧に維持することを特徴とする請求項9に記載の炭酸ガスミスト圧浴装置。
- 前記炭酸ガスミスト包囲手段は、前記炭酸ガスミストを内部に封印する空間を形成する、折り畳み可能なカバータイプ、袋体タイプ又は固定据置型のボックスタイプの何れかの包囲手段である請求項7に記載の炭酸ガスミスト圧浴装置。
- 前記炭酸ガスミスト包囲手段は、
その内部に前記炭酸ガスミストを導入するための、内部に逆止弁を有する炭酸ガスミスト供給口と、
内部の気体を排出するための排出口と、
生体が出入りするための出入口と、前記ボックス本体内から生体の頭部を露出させるための開口と、
を備えることを特徴とする請求項13に記載の炭酸ガスミスト圧浴装置。 - 前記開口には、当該開口と生体の隙間からの炭酸ガスミストの漏出を防ぐ漏出防止手段を設けることを特徴とする請求項14に記載の炭酸ガスミスト圧浴装置。
- 前記ボックスタイプの炭酸ガスミスト包囲手段は、その内部に椅子を備えることを特徴とする請求項13に記載の炭酸ガスミスト圧浴装置。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127032790A KR20130128310A (ko) | 2010-12-20 | 2011-12-20 | 생체의 허혈 영역의 혈행 상태를 개선 또는 촉진하기 위한 탄산 가스 미스트 압욕 방법 및 탄산 가스 미스트 압욕 장치 |
BR112012032386A BR112012032386A2 (pt) | 2010-12-20 | 2011-12-20 | método, e, aparelho de banho de pressão de névoa de gás de dióxido de carbono |
EP11851069.2A EP2586418A4 (en) | 2010-12-20 | 2011-12-20 | CARBON DIOXIDE GAS PRESSURE STEAM METHOD AND CARBON DIOXIDE GAS PRESSURE STEAM BATH APPARATUS FOR ENHANCING AND PROMOTING BLOOD CIRCULATION IN AN ISCHEMIC REGION OF THE ORGANISM |
US13/701,720 US9289352B2 (en) | 2010-12-20 | 2011-12-20 | Carbon dioxide gas mist pressure bath apparatus for improving or promoting circulation of blood in ischemic region of living organism |
JP2012549825A JPWO2012086636A1 (ja) | 2010-12-20 | 2011-12-20 | 生体の虚血領域の血行状態を改善又は促進するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 |
CN201180030960.7A CN103025296B (zh) | 2010-12-20 | 2011-12-20 | 用于改善或促进机体的缺血区域的血液循环状态的二氧化碳雾压浴方法以及二氧化碳雾压浴装置 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-283832 | 2010-12-20 | ||
JP2010283832 | 2010-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012086636A1 true WO2012086636A1 (ja) | 2012-06-28 |
Family
ID=46313905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/079486 WO2012086636A1 (ja) | 2010-12-20 | 2011-12-20 | 生体の虚血領域の血行状態を改善又は促進するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9289352B2 (ja) |
EP (1) | EP2586418A4 (ja) |
JP (1) | JPWO2012086636A1 (ja) |
KR (1) | KR20130128310A (ja) |
CN (1) | CN103025296B (ja) |
BR (1) | BR112012032386A2 (ja) |
WO (1) | WO2012086636A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012086635A1 (ja) * | 2010-12-20 | 2014-05-22 | 中村 正一 | 心筋梗塞を予防、改善又は治療するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3044090A1 (en) * | 2016-11-18 | 2018-05-24 | Aqua Pur Tubs Incorporated | Methods and apparatus for generating gas bubbles |
SG11201908087TA (en) | 2017-01-31 | 2019-10-30 | Berta Zsolt Zoltan | Apparatus for transcutaneous treatment by gas |
RS63064B1 (sr) * | 2019-12-24 | 2022-04-29 | Derma Art Doo | Uređaj za transkutanu primenu ugljen dioksida |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07171189A (ja) | 1993-12-17 | 1995-07-11 | Matsushita Electric Works Ltd | 血行促進装置 |
JP2006263253A (ja) | 2005-03-25 | 2006-10-05 | Matsushita Electric Works Ltd | 血行促進装置 |
JP2009183625A (ja) | 2008-02-08 | 2009-08-20 | Shoichi Nakamura | 炭酸ガス圧浴装置 |
WO2009157538A1 (ja) * | 2008-06-27 | 2009-12-30 | 日本エー・シー・ピー株式会社 | ガスミスト圧浴装置 |
JP3163836U (ja) * | 2010-08-23 | 2010-11-04 | 中村 正一 | ガスミスト圧浴用ボックス |
JP3163837U (ja) * | 2010-08-23 | 2010-11-04 | 中村 正一 | ガスミスト圧浴用カバー |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE67661C (de) * | Dr. E. LUH-MANN in Andernach und C. G. ROMMENHÖLLER, General- Konsul, in Rotterdam | Vorrichtung zur Verabfolgung von gasförmigen Kohlensäurebädern | ||
DE2062632A1 (de) * | 1970-12-18 | 1972-06-29 | Paul Ritzau Pari-Werk KG, 8135 Söcking | Inhalationsgerät |
DE20307743U1 (de) * | 2002-05-24 | 2003-09-25 | Kovarik Robert | Vorrichtung für die nicht medizinische CO2-Gasbehandlung von Personen |
ES2592274T3 (es) * | 2006-03-30 | 2016-11-29 | Carefusion 2200, Inc. | Nebulizador con control de fluido basado en el flujo |
BRPI0822569A2 (pt) * | 2008-04-09 | 2015-06-23 | Bio Bath Corp | Aparelho móvel para a dispersão e entrega transdérmica de gás de dióxido de carbono farmacêutico, médico ou purificado |
KR20110098709A (ko) * | 2008-12-04 | 2011-09-01 | 쇼이치 나카무라 | 가스 미스트 압욕 시스템 |
JP5473942B2 (ja) * | 2008-12-10 | 2014-04-16 | 正一 中村 | ガスミスト圧浴システム |
WO2010073754A1 (ja) * | 2008-12-26 | 2010-07-01 | 日本エー・シー・ピー株式会社 | 炭酸ガスミスト圧浴システム |
WO2010090210A1 (ja) * | 2009-02-06 | 2010-08-12 | 日本エー・シー・ピー株式会社 | ガスミスト圧浴システム |
CN102159168B (zh) * | 2009-02-19 | 2014-02-19 | 中村正一 | 气雾压浴系统 |
US9271894B2 (en) * | 2010-12-20 | 2016-03-01 | Advance Biotron Co., Ltd. | Carbon dioxide gas mist pressure bath apparatus for preventing, improving or curing myocardial infarction |
-
2011
- 2011-12-20 JP JP2012549825A patent/JPWO2012086636A1/ja active Pending
- 2011-12-20 BR BR112012032386A patent/BR112012032386A2/pt not_active IP Right Cessation
- 2011-12-20 KR KR1020127032790A patent/KR20130128310A/ko not_active Application Discontinuation
- 2011-12-20 CN CN201180030960.7A patent/CN103025296B/zh not_active Expired - Fee Related
- 2011-12-20 US US13/701,720 patent/US9289352B2/en not_active Expired - Fee Related
- 2011-12-20 WO PCT/JP2011/079486 patent/WO2012086636A1/ja active Application Filing
- 2011-12-20 EP EP11851069.2A patent/EP2586418A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07171189A (ja) | 1993-12-17 | 1995-07-11 | Matsushita Electric Works Ltd | 血行促進装置 |
JP2006263253A (ja) | 2005-03-25 | 2006-10-05 | Matsushita Electric Works Ltd | 血行促進装置 |
JP2009183625A (ja) | 2008-02-08 | 2009-08-20 | Shoichi Nakamura | 炭酸ガス圧浴装置 |
WO2009157538A1 (ja) * | 2008-06-27 | 2009-12-30 | 日本エー・シー・ピー株式会社 | ガスミスト圧浴装置 |
JP3163836U (ja) * | 2010-08-23 | 2010-11-04 | 中村 正一 | ガスミスト圧浴用ボックス |
JP3163837U (ja) * | 2010-08-23 | 2010-11-04 | 中村 正一 | ガスミスト圧浴用カバー |
Non-Patent Citations (1)
Title |
---|
See also references of EP2586418A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2012086635A1 (ja) * | 2010-12-20 | 2014-05-22 | 中村 正一 | 心筋梗塞を予防、改善又は治療するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 |
Also Published As
Publication number | Publication date |
---|---|
KR20130128310A (ko) | 2013-11-26 |
BR112012032386A2 (pt) | 2016-11-08 |
US9289352B2 (en) | 2016-03-22 |
CN103025296A (zh) | 2013-04-03 |
US20130079703A1 (en) | 2013-03-28 |
EP2586418A1 (en) | 2013-05-01 |
EP2586418A4 (en) | 2014-04-02 |
JPWO2012086636A1 (ja) | 2014-05-22 |
CN103025296B (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4922459B2 (ja) | ガスミスト圧浴システム | |
JP5088905B2 (ja) | ガスミスト圧浴システム | |
WO2012086635A1 (ja) | 心筋梗塞を予防、改善又は治療するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 | |
JP3163837U (ja) | ガスミスト圧浴用カバー | |
JP5406214B2 (ja) | 炭酸ガスミスト圧浴システム | |
JP5088906B2 (ja) | 炭酸ガスミスト圧浴システム | |
JP5995373B2 (ja) | ガスミスト圧浴システム | |
WO2012086636A1 (ja) | 生体の虚血領域の血行状態を改善又は促進するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 | |
JP3163836U (ja) | ガスミスト圧浴用ボックス | |
JP5474042B2 (ja) | ガスミスト圧浴システム | |
JP5102377B2 (ja) | ガスミスト圧浴システム | |
JP5305550B2 (ja) | ガスミスト圧浴システム | |
WO2010074198A1 (ja) | ガスミスト圧浴用カバー | |
KR20110098710A (ko) | 가스 미스트 압욕 시스템 | |
JP5743587B2 (ja) | ガスミスト圧浴システム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180030960.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11851069 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012549825 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011851069 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13701720 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10883/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127032790 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012032386 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012032386 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121218 |